BioTuesdays

Category - Markets

Autolus Logo
Markets

HCW starts Autolus Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...

October 24, 2018
Gritstone Oncology
Markets

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

October 23, 2018
IntelGenx Logo
Markets

IntelGenx completes $12-million equity offering

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT)completed an offering of 17,144,314 units at a price of 70 (U.S.) cents each for gross proceeds of approximately $12-million. Each unit consists of one common share of...

October 22, 2018
Ra Medical
Markets

Piper Jaffray starts Ra Medical at OW; PT $23

Piper Jaffray initiated coverage of Ra Medical Systems (NASDAQ:RMED) with an “overweight” rating and price target of $23. The stock closed at $13.25 on Oct. 19. Ra makes and sells excimer laser products. While it has a...

October 22, 2018
Titan Pharmaceuticals Logo
Markets

Titan Pharma shares jump 33% on initiation by A.G.P.

Shares of Titan Pharmaceuticals (NASDAQ:TTNP) jumped 33% to close at 32 cents on Oct. 18 after A.G.P./Alliance Global Partners initiated coverage of Titan with a “buy” rating and price target of 45 cents. Turnover was a...

October 19, 2018
Y-mAbs Therapeutics Logo
Markets

BTIG starts Y-mAbs Therapeutics at buy; PT $35

BTIG launched coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and $35 price target. The stock closed at $21.60 on Oct. 15. Y-mAbs is in pivotal trials for the treatment of both primary neuroblastomas...

October 16, 2018
KalVista Pharmaceuticals Logo
Markets

Stifel starts KalVista Pharma at buy; PT $33

Stifel initiated coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $33 price target. The stock closed at $18.76 on Oct. 12. “Our bullish thesis on the stock centers around lead asset, KVD900, an...

October 15, 2018
Vascular Biogenics
Markets

HCW ups Vascular Biogenics to buy; PT $3

H.C. Wainwright upgraded Vascular Biogenics (NASDAQ:VBLT) to “buy” from “neutral” but maintained its $3 price target, citing a 46% stock price decline since March, despite no negative news. The stock closed at $1.42 on...

October 15, 2018
Profound Medical Logo
Markets

Echelon names Profound Medical as Top Pick

Echelon Wealth Partners has named Profound Medical (TSX:PRN; OTCQX:PRFMF) as a Top Pick with a “buy” rating and $3 price target. The stock closed at 60 cents on Oct. 10. Commenting on Profound’s share price softness in...

October 12, 2018
Immune Design
Markets

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

October 12, 2018